


Diabetes in early childhood – more than type 1 diabetes

Diabetesforum, 26.04.17

Pål R. Njølstad MD PhD
KG Jebsen Center
for Diabetes Research




Precision medicine in diabetes



- Approach for disease prevention, diagnosis and treatment
- Individual variability in environment, lifestyle and biology

The Norwegian MODY Registry



Monogenic diabetes 2017 - many

genes

- 6q24
- EIF2AK3
- FOXP3
- GATA6
- GLIS3
- IER3IP1
- IL2RA
- NEUROG3
- NKX2.2
- MNX1
- PAX6
- PTF1A
- RFX6
- SLC2A2
- SLC19A2
- WFS1
- ZFP57

NDM

- Age of onset <6 months
- Autosomal dominant or recessive
- β -cell failure

NDM plus organ dysfunction

- Bone
- Blood
- Cardiovascular system
- Central nervous system
- Endocrine system
- Exocrine pancreas
- Eye
- Gastrointestinal system
- Genitalia
- Kidney
- Skin

MODY

- Age of onset 6 months – 35 years
- Autosomal dominant
- β -cell failure



MODY plus organ dysfunction

- Adipose tissue
- Blood
- Cardiovascular system
- Central nervous system
- Exocrine pancreas
- Gastrointestinal system
- Genitalia
- Kidney
- Lung


- MT-TE
- MT-TK
- MT-TL1

Mitochondrial diabetes mellitus

- Deafness
- Mitochondrial inheritance



A simpler picture....



GCK: Neonatal diabetes is a genetic disease






Photo: Jan M. Lillebø, Bergens Tidende


- Neonatal diabetes is a genetic disorder
- Affects insulin-producing beta cells
- Patients need insulin for life

Neonatal diabetes can be due to *KCNJ11* mutations



- Mutations in *KCNJ11* can cause neonatal diabetes
- Can the oral drug sulfonylurea replace insulin?



Changing medical practice



TV2, 2006


Children can avoid painful injections
Metabolic control is improved (HbA_{1c} 2%-points lower)
Reduced risk for long-term complications

10 y sulfonyleurea treatment is efficient and safe



Kaplan-Meier survival estimate – 94% remaining on SU only

Neonatal diabetes due to *ABCC8* mutations



K_{ATP} channel (*ABCC8*)




Sulfonylurea

- Adopted from Columbia, "T1D", discovered at yearly control
- Very small doses of sulfonylurea needed to replace insulin

HNF1A and GCK MODY have different clinical course

HNF1A




GCK

Sagen et al, Ped Diabetes 2008; Bjørkhaug et al, JCEM 2003

HNF1A and GCK MODY have different clinical course

HNF1A

- Progressive diabetes
- High risk for diabetes complications
- Sulfonylurea tablets and/or insulin



- Stable diabetes
- No risk for diabetes complications
- No treatment

GCK





HNF1B MODY and early preventive treatment

HNF1B


- Progressive kidney failure
- Pancreas aplasia
- Diabetes +/-
- Insulin



- Early preventive and supportive treatment




The Norwegian Childhood Diabetes Registry




Monogenic screen in childhood diabetes

Exome sequencing of gene panel

- Monogenic diabetes genes
- 938 children with diabetes
 - 469 antibody negative
 - 469 antibody positive
- Bioinformatics score for pathogenicity



Childhood "type 1 diabetes" can be monogenic diabetes



Implication for diagnosis and treatment?

- 6.5% mutation in a monogenic gene – most *HNF1A*
- Are these sensitive to sulfonylurea tablets?

○ Functional studies and treatment trial under [Naimi et al, Diabetes 2017](#); [B Johansson et al, Diabetologia 2017](#); Thor Bentzen, Åsta Sulen, unpublished

When to think monogenic diabetes?

Neonatal diabetes

- Less than 6 months: Neonatal diabetes!
- 80% genetic dx

MODY

- Age of diagnosis 6 months – 35 years
- Parent with diabetes of any kind, (BMI)
- Negative GAD/IA-2, elevated C-peptides
- 40% genetic dx

Genetic testing

- Haukeland University Hospital
- Next-generation panel sequencing, 2 weeks

KG JEBSEN CENTER FOR DIABETES RESEARCH



www.mody.no

Bergen Group - past & present A Molven, O Søvik, L Bjørkhaug, K Fjeld, S Johansson, B Johansson, H Ræder, J Sagen, T Sandal, J Molnes, M Vesterhus, J Torsvik, JK Hertel, E Tjora, A Ragvin, K Chudasama, M Negahdar, T Hoang, L Najmi, M Dalva, G Helgeland, Ø Helgeland, H Irgens, I Aukrust, M Vaudel, A Kaci, G Mellgren, O Nygård, J Fernø, M Solheim, L Aasmul, M Holmaas, A Hammer

Others from Norway K Dahl-Jørgensen, G Joner, T Skrivarhaug, DE Undlien, PM Thorsby, I Nerموen, I Følling, K Midthjell, K Hveem, O Holmen, C Platou, T Claudi, D Aarskog, I Haldorsen, C Stoltenberg, P Magnus, GP Knutsen, LC Stene

Abroad GI Bell (Chicago), (Joslin, Boston), N Beer, AT Hattersley, AL Gloyn, S Ellard (UK), D Lombardo, M Polak (France), FM Matschinsky, CA Stanley (Philadelphia), N Shehadeh (Israel), A Cuesta-Muñoz (Spain), T Hansen, O Pedersen, H Mortensen (Denmark), T Tuomi (Finland), L Groop, M Orho-Melander, V Lyssenko (Sweden), R Kahn, R Kulkarni, J Winnay, D Altshuler, J Flannick, A Manning, T Rolph, J Hirschhorn, CE & JG Seidman, S